Accuray Inc. Release: Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption

SUNNYVALE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. Usage of CyberKnife radiosurgery for lung cancer continues to grow, as illustrated by a 25 percent increase year over year in calendar year 2009.
MORE ON THIS TOPIC